Sequence: Acetyl-KC(cRGDfC)ULKLULKULKAC(cRGDfC)LKLUG-NH2
| Experiment Id | EXP000642 |
|---|---|
| Paper | Design of cyclic RGD-conjugated Aib-containing amphipathic helical peptides for targeted delivery of |
| Peptide | PIII |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 1.0 µM |
| Rna Concentration | 10 nM |
| Mixing Ratio | 100 |
| Formulation Format | electrostatic peptide/siRNA complex |
| Formulation Components | cRGDfC–MAP(Aib) conjugate peptide + siRNA (complex formed by electrostatic interaction) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | A549; A549-Luc (luciferase-expressing A549) |
| Animal Model | |
| Administration Route | |
| Output Type | reporter knockdown (luciferase) |
| Output Value | 15% suppression after extended incubation (48 h); no knockdown at 24 h under standard condition |
| Output Units | |
| Output Notes | Uptake/CLSM: strong uptake in A549; predominantly punctate fluorescence; strong colocalization with LysoTracker (endosomal/lysosomal localization). RNAi: no effect at 24 h post-treatment (8 h incubation + 24 h culture) even at ratios 100/50/20; extending culture to 48 h gave ~15% suppression; 72 h reduced again. |
| Toxicity Notes | No significant LDH release reported vs control at 1.0 µM/10 nM (ratio 100). |
| Curation Notes |